Hepatocellular Cancer Clinical Trial
Official title:
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
Patients with HCC with portal vein involvement not involving the bifurcation (vP1-vP3) and no evidence of extra-hepatic spread will be enrolled. Patients will be required to have Child's A liver function and no significant portal hypertension. Patients will be randomly assigned with a 1:1 ratio to either surgery followed by adjuvant sorafenib or sorafenib alone. Patients will be followed by serial imaging. The primary end-point is overall survival.
Trial design Surgery + sorafenib vs. sorafenib 100 patients per arm Centralized randomization by CRO Need to call CRO for treatment allocation Primary end-point - OS Secondary end-point Progression free survival (PFS) Randomized 1:1 Stratification Vp1-2 vs. Vp3 AFP ≤400 vs AFP >400 Intention to treat Surgery aborted or R1-2 resection will remain in surgical arm No cross over CT scan chest/abdomen 4 weeks after surgery as post-operative baseline Will not alter treatment allocation Will allow for PFS measurement in surgical arm CT scan chest/abdomen pelvis Q 12 weeks after initiation sorafenib Patients progressing on sorafenib allowed 2nd line treatment Regorafenib or lenvatinib - if approved in China Dose reduction sorafenib as per protocol ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
| Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
| Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
| Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
| Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
| Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
| Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
| Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
| Completed |
NCT00997022 -
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
|
Phase 1 | |
| Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 |